Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen’s inflammatory bowel disease treatment is hitting the curb after the biotech had difficulty nailing a safe dose in healthy volunteers.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...
Surrozen’s fiscal tightening has continued through the year, with the biotech cutting two preclinical assets to focus on two meds already in trials.
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while...
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...